1. ScholarBank@NUS

Pei Shi Ong

rp10093

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Pei Shi Ong
Variants
Ong, P.S.
Ong, P.-S.
 
Main Affiliation
 
Faculty
 
Email
phaops@nus.edu.sg
 

Publications

Results 1-14 of 14 (Search time: 0.011 seconds).

Issue DateTitleAuthor(s)
130-Jan-2013A miniaturized flow-through cell to evaluate skin permeation of endoxifenMah, C.S.; Kochhar, J.S.; Ong, P.S. ; Kang, L. 
22018Access and adherence to medications for the primary and secondary prevention of atherosclerotic cardiovascular disease in singapore: A qualitative studyKoh, J.J.K. ; Cheng, R.X.; Yap, Y.; Haldane, V. ; Tan, Y.G.; Teo, K.W.Q.; Srivastava, A. ; Ong, P.S. ; Perel, P.; Legido-Quigley, H. 
32016Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its developmentWang, L ; Khoa Phan, D.D; Zhang, J; Ong, P.-S ; Thuya, W.L ; Soo, R.A ; Wong, A.L.-A ; Yong, W.P ; Lee, S.C ; Ho, P.C.-L ; Sethi, G ; Goh, B.C 
4Aug-2012Clinical therapeutics for phenylketonuriaKochhar, J.S.; Chan, S.Y. ; Ong, P.S. ; Kang, L. 
51-Oct-2003Current trends in modern pharmaceutical analysis for drug discoveryKoh, H.-L. ; Yau, W.-P. ; Ong, P.-S. ; Hegde, A.
6Jun-2011Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: Oxidative stress-independent and -dependent cytotoxic potentiationOng, P.-S. ; Chan, S.-Y. ; Ho, P.C. 
714-Feb-2012Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As 2O 3 and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsROng, P.-S. ; Chan, S.-Y. ; Ho, P.C. 
82019Perspectives on acceptance and use of a mobile health intervention for the prevention of atherosclerotic cardiovascular disease in singapore: mixed-methods studyHaldane, V.; Tan, Y.G.; Teo, K.W.Q.; Koh, J.J.; Srivastava, A.; Cheng, R.X.; Yap, Y.C.; Ong, P.-S. ; van Dam, R.M.; Foo, J.M.; Müller-Riemenschneider, F.; Koh, G.C.-H.; Perel, P.; Legido-Quigley, H.
918-Jul-2021Prescribing patterns, efficacy and safety of DOAC usage in a tertiary hospitalYong, Kar Ying; Leow, Shirlene; Yap, Eng Soon; Ong, Pei Shi ; Tan, Su Ching ; Goh, Pik Wei
1018-Jan-2013Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: Application to a pharmacokinetic studyLin, H.-S. ; Sviripa, V.M.; Watt, D.S.; Liu, C.; Xiang, T.-X.; Anderson, B.D.; Ong, P.S. ; Ho, P.C. 
111-Sep-2021Resveratrol for cancer therapy: Challenges and future perspectivesRen, Boxu; Kwah, Marabeth Xin-Yi; Liu, Cuiliu; Ma, Zhaowu; Shanmugam, Muthu K. ; Ding, Lingwen ; Xiang, Xiaoqiang; Ho, Paul Chi-Lui ; Wang, Lingzhi ; Ong, Pei Shi ; Goh, Boon Cher 
1220-Sep-2018Safety and Effectiveness of Azathioprine in Patients with Inflammatory Bowel Disease (IBD) in SingaporeFoo, Elston; Gan, Jia-min; Ong, Wan-chee; Chan, Webber ; Shim, Hang-hock ; Ong, Pei-Shi ; Lim, Teong-Guan 
13May-2012Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cellsOng, P.-S. ; Wang, X.-Q.; Lin, H.-S. ; Chan, S.-Y. ; Ho, P.C. 
142019User preferences and persona design for an mhealth intervention to support adherence to cardiovascular disease medication in singapore: A multi-method studyHaldane, V.; Koh, J.J.K. ; Srivastava, A. ; Teo, K.W.Q.; Tan, Y.G.; Cheng, R.X.; Yap, Y.C.; Ong, P.-S. ; van Dam, R.M. ; Foo, J.M. ; Müller-Riemenschneider, F. ; Koh, G.C.-H. ; Foong, P.S. ; Perel, P.; Legido-Quigley, H.